Percutaneous microwave ablation for hepatic cavernous hemangiomas: a preliminary clinical result
Keywords:
microwave ablation, hepatic cavernous hemangioma, ultrasound guidanceAbstract
Purpose: To explore the clinical application value of microwave (MW) ablation treatment for hepatic cavernous hemangiomas (HCHs) under percutaneous ultrasound (US) guidance. Methods: From July 2006 to January 2011, 14 patients (9 female and 5 male) with 18 HCHs (mean maximum diameter, 36.6±26.1 mm) were treated by MW ablation under US-guidance percutaneously. The diagnoses of HCHs were proven pathologically in 78.6% (11/14) patients by US-guided core needle biopsy prior to ablation. The other 3 cases refused biopsy and had their diagnoses confirmed by typical presentations on contrast-enhanced imaging. Four inclusion criteria including symptoms related to HCH were recommended. The follow-up period was 22.7±16.0 months. Results: Average ablation MW energy and emission time were 55.2±53.3 kJ (range 13.5 to 207 kJ) and 1021.3±886.4 s (range 270 to 3450 seconds) for each lesion, respectively. Fifteen nodules (83.3%) were completely treated and no evidence of recurrence was found on contrast enhanced imaging during follow-up. The three large HCHs (16.7%) were partially ablated as being adjacent to the gastrointestinal tracts or an important hepatic hilum structure. After ablation, three patients’ symptoms relating to HCHs were alleviated in differing degrees. No severe complications occurred in the peri-operation or follow-up periods. Minor complications mainly included fever, local pain and abnormal hepatic function. Conclusion: US-guided percutaneous MW ablation is a safe, feasible and effective treatment for selected patients with HCHs and can be considered as a minimally invasive alternative to surgical resection.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.